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Proton therapy has become an increasingly more common method of radiation 
therapy, with the dose sparing to distal tissue making it an appealing option, particularly 
for treatment of brain tumors. This study sought to develop a head phantom for the 
Radiological Physics Center (RPC), the first to be used for credentialing of institutions 
wishing to participate in clinical trials involving brain tumor treatment of proton therapy. 
It was hypothesized that a head phantom could be created for the evaluation of proton 
therapy treatment procedures (treatment simulation, planning, and delivery) to assure 
agreement between the measured dose and calculated dose within ±5%/3mm with a 
reproducibility of ±3%. The relative stopping power (RSP) and Hounsfield Units (HU) 
were measured for potential phantom materials and a human skull was cast in tissue-
equivalent Alderson material (RLSP 1.00, HU 16) with anatomical airways and a 
cylindrical hole for imaging and dosimetry inserts drilled into the phantom material. Two 
treatment plans, proton passive scattering and proton spot scanning, were created. 
Thermoluminescent dosimeters (TLDs) and film were loaded into the phantom dosimetry 
insert. Each treatment plan was delivered three separate times. Each treatment plan 
passed our 5%/3mm criteria, with a reproducibility of ±3%. The hypothesis was accepted 
and the phantom was found to be suitable for remote audits of proton therapy treatment 
facilities. 
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Chapter 1 
1 Introduction and Background 
1.1  Statement of Problem 
1.1.1 General Problem Area 
 
With about 2500 medical facilities treating over a million cancer patients with 
radiation therapy modalities in the United States each year, there is a need to assure that 
the treatment a patient gets in one area of the country is of the highest quality and not 
significantly different than what one would expect to receive in another region (1). 
Similarly, if institutions are participating in National Cancer Institute (NCI) funded 
clinical trials involving radiation therapy trials, there needs to be some way of assuring 
the specific Study Groups sponsoring the trials that each site is qualified and capable of 
following the requirements of trial protocols. With over 1800 institutions participating in 
more than 100 clinical trials involving radiation therapy, there are a significant number of 
patients affected by the quality of radiation treatment. Treatment facilities are already 
encouraged to carry out their own quality assurance (QA) programs, per 
recommendations published by the International Commission on Radiation Units and 
Measurements (ICRU) and contained in the American Association of Physics in 
Medicine Task Group reports (AAPM TG reports), but there are currently very few 
groups that assure excellence and consistency between independent radiation treatment 
centers across North America.  
The Radiological Physics Center (RPC), based at MD Anderson Cancer Center in 
Houston, TX, is a QA group funded by the NCI who is charged with monitoring medical 
institutions participating in clinical trials. The RPC was created with the goal of  assuring 
the NCI and cooperative clinical trial Study Groups that radiation dose delivered to trial 
patients are “clinically comparable and consistent” (2). The RPC, unlike other QA groups 
funded by the NCI who only monitor a fraction of the trial participants, monitors all 
participating institutions (nearly 1850 sites) that participate in all cooperative group 
clinical trials funded by the NCI. The RPC uses both onsite audit visits and remote 
mailable dosimetric audit systems to assess the efficacy of each institution’s radiation 
therapy procedures. The remote audit mailable program includes: (1) verification of an 
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institution’s machine output using thermoluminescent detectors (TLDs) or optically 
stimulated luminescent detectors, (2) Verification of the patient treatment records sent to 
the RPC for review and (3) Credentialing institutions through the use of the RPC’s 
anthropomorphic QA phantoms that evaluate an institution’s ability to deliver a specific 
treatment end to end, i.e. from imaging to planning to setup to dose delivery.   The RPC 
has numerous phantoms for photon therapies, including SRS head, head & neck, spine, 
thoracic/lung, pelvic/prostate, and liver phantoms, but very few for proton therapy. 
1.1.2 Specific Problem 
 
Radiation Oncology therapy as given today is highly dependent on advances in 
technology and computerization of treatments. One of the advanced technologies used to 
treat patients is proton therapy. Although proton therapy has been around for some time, 
recent advances in delivery techniques such as scanning beams and intensity modulated 
proton therapy, have increased its popularity in the Radiation Oncology community, 
particularly in the United States. According to the National Association for Proton 
Therapy (3), there are currently nine proton centers treating patients, four more under 
construction, and another 8-10 in the planning stages whereas only 5 years ago there were 
only 3 centers treating patients. As proton therapy becomes more widely used to treat 
certain types of patients, this form of therapy will be included as a radiation delivery 
option in NCI funded clinical trials. As proton facilities look to enroll patients in clinical 
trials, there is a need to evaluate each institution’s ability to provide accurate, precise and 
consistent treatments. 
The NCI wants the scientific integrity of its clinical trials to be flawless and as 
such has funded several quality assurance groups to assist the Study Groups and to 
monitor those institutions participating in clinical trials. One monitoring group, the 
Quality Assurance Review Center (QARC), provides treatment record quality assurance 
and data management for six NCI cooperative groups(4). Because of QARC’s 
relationship with the Children’s Oncology Group (COG), it has been involved in 
providing some proton therapy QA through the use of a questionnaire and proton therapy 
benchmark case. The questionnaire allows QARC to assess the institution’s resources, 
personnel and experience, while the benchmark case gives them confidence that the 
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institution can properly generate a treatment plan given guidance from a protocol (4). 
While QARC and other monitoring bodies review records and monitor safety protocol 
and violations, the RPC is the only group that oversees the quality of radiation therapy.   
As such, the RPC is the quality assurance group best suited to develop a 
credentialing process for the evaluation of proton therapy. Generally the RPC 
credentialing procedure includes a site visit to the institution of interest where 
measurements are taken using phantoms and dosimeters to assess the quality of radiation 
therapy being delivered at the facility. With the introduction of proton therapy in clinical 
trials, the RPC adapted two phantoms for the use in proton credentialing: a pelvis and 
lung phantom (5, 6). The lung phantom had been modified with the use of balsa wood as 
a lung-equivalent material, due to the similarities between balsa wood’s stopping power 
and CT number in relation to the lungs’ correlating properties. The pelvic phantom was 
similarly modified by changing the target and critical structure phantom materials to 
more closely mimic corresponding anatomy based on stopping power and CT numbers. 
The phantoms test the proton systems ability to deliver a conformal dose to a target, and 
in the case of the pelvis phantom, avoid dose to surrounding critical structures. While 
dosimetric methods and QA phantoms for testing radiation therapy facilities have adapted 
to new developments in treatment modalities including proton therapy, the RPC does not 
at this time have a mailable anthropomorphic head & neck phantom available to test 
proton therapy treatment.  
1.1.3 Importance of Topic 
 
Quality control of radiation therapy is of utmost importance in assuring proper 
treatment of patients as well as the safety of patients and personnel in the radiation 
oncology field. However, the role of quality control has taken on new importance with 
the lay press drawing increasing attention to radiation therapy incidents and medical 
errors. A series of articles published in The New York Times in the Winter of 2010 
exposed malpractice and radiation therapy errors, some of which led to serious 
complications as well as fatalities of patients who had been mistreated (7, 8). From there, 
the media has continued to draw attention to dangers of radiation oncology and there has 
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been heightened skepticism of radiation therapy practices both by media sources and the 
general public.  
As delineated in one of the articles, new modalities are often accepted for use in 
treating patients with little attention to how safety and quality assurance procedures may 
have to be changed based on the newly employed advanced technology (7). Recognizing 
that proton therapy requires distinctive QA procedures, the ICRU recommends quality 
assurance checks for proton therapy that cover the treatment delivery system, patient 
positioning and immobilization, and treatment planning (9). However, most centers using 
proton therapy generally develop their own quality assurance practices specific to their 
unique setup (e.g. different tests for passively scattered beams v. scanning beams, etc.) 
following the basic principles laid out in the ICRU recommendations. Due to the variety 
of QA programs and measurement techniques throughout the existing proton therapy 
institutions, an independent evaluation of the accuracy of treatment delivery at each 
center is needed if they are to participate in clinical trials. One technique to perform this 
independent evaluation is through the use of one of the RPC’s anthropomorphic QA 
phantoms built especially for proton therapy. Once the QA phantom is developed by the 
RPC, it will be beneficial in ensuring nationwide treatment conformity, as well as 
compliance of the radiation therapy centers participating in research protocols. 
Quality assurance for proton therapy is just as, if not more, important as quality 
assurance for other radiation therapy modalities. While the behavior of the proton Bragg 
peak makes protons great for killing cancer cells, it also has a great potential to damage 
healthy tissue if the range of the proton beam is miscalculated and regular tissue is 
accidentally irradiated. Proton therapy, as mentioned in the introduction, has unique 
requirements for quality assurance because different facilities have different machines 
and equipment. In regards to beam calibration, it is recommended by the ICRU, and 
required by the NCI for centers participating in cooperative group trials, that each proton 
beam be calibrated according to TRS 398. This protocol walks each center through the 
determination of the absorbed dose to water for the proton beam using a parallel plate or 
cylindrical ion chamber, depending on the residual range (10). 
Regular quality assurance procedures, however, have looser guidelines, as each 
facility has set up their own method of checking the accuracy and precision of their 
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proton therapy treatment system. The ICRU has summarized some suggested quality 
assurance procedures for both passive and scanning beam systems, as collected from site-
specific QA publications. These recommendations include daily checks of the beam 
aperture alignment, room lasers, safety interlocks, patient communication systems and 
patient positioning, depth dose and lateral beam profiles, monitor units and dose 
monitors, and individual patient treatment setup, with additional checks required for 
scanning beam systems, including dose rate, monitor ratios, beam position monitors, 
depth dose curves in water, and calibration of the primary dose monitor (9). Weekly 
checks include patient positioning and imaging modalities, beam-line apparatus, breath 
cycle equipment, and verification of one patient dose in water (to be examined in three 
dimensions for scanning beams) (9). Semi-annual, annual, or scheduled checks include 
calibration of CT scanner Hounsfield units, x-ray alignment, tests of all therapy 
equipment, and calibration of the primary dose monitor, and beam characteristics for 
scanning beams (9). While most facilities follow these general practices, there is room for 
variation as each center employs equipment developed by different manufacturers. 
While it is not possible at this time to get every proton center to follow the exact 
same quality assurance protocol, which might ensure consistency in performance across 
centers, it is possible to review each center’s performance to ensure that their 
individualized QA procedures are working. Beyond a uniform initial beam calibration, 
the NCI has set forth additional guidelines for proton therapy centers looking to 
participate in clinical trials. The NCI requires that these centers go through a 
credentialing process with the RPC for the cooperative group running the trial. The 
centers undergo a credentialing process through the RPC that includes several steps. 
These steps include completion of a questionnaire, annual monitoring of the reference 
proton beam outputs with the RPC’s TLD audit and dosimetry onsite visits that include 
dosimetry measurements, review of QA procedures and a phantom irradiation. Part of the 
RPC’s visit is to assure accuracy of the proton center’s Hounsfield to Stopping Power 
conversion, treatment planning algorithm, and patient specific immobilization system 
(11). There are a handful of other guidelines put forth by the NCI as well: a radiation 
oncologist must be involved in the implementation of the clinical trial at each institution, 
all doses must be expressed in terms of Cobalt Gray Equivalent (CGE) using an RBE of 
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1.1, and while GTV and CTV for treatment planning must be the same as it would for 
photon protocol, the PTV created for each lesion should take into account site-specific 
beam characteristics, such as lateral beam scattering and range uncertainties (11).  
1.2 Hypothesis 
With the current relevance and importance of proton therapy quality assurance, 
this project is particularly timely.  The hypothesis of this project is as follows: An 
anthropomorphic head phantom can be created to evaluate proton therapy treatment 
procedures (patient simulation, treatment planning, and treatment delivery) to assure 
agreement between the measured dose and calculated dose within ±5%/3mm with a 
reproducibility of ±3%. With this goal in mind, the specific aims of this project are: 
1. Select a suitable head phantom design, evaluate tissue equivalent materials for 
corresponding relevant patient anatomy and build the head phantom. 
2. Image the head phantom, create two clinically relevant proton therapy treatment 
plans using the passive scattered and spot scanning proton beams, and irradiate 
the phantom multiple times with each treatment plan. 
3. Measure the delivered dose distribution and the dose to specific points inside the 
irradiated phantom. 
4. Compare the measured and calculated point doses and 2D dose distributions to 
determine deviations and precision. 
1.3 Research Approach 
In order to achieve the specific aims of the project, the following methodology 
will be employed: 
1. The stopping power and Hounsfield Units (HU) will be determined for the 
phantom materials and compared to known stopping powers and Hounsfield Units 
of corresponding human anatomy used for proton therapy. 
2. The phantom will be imaged with MRI and this image will be fused with a CT 
image set for target delineation and dose distribution calculations. Two treatment 
plans will be designed using these images in the Eclipse proton planning system, 
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according to the department’s standards for both the passive scattering and spot 
scanning systems. The plans will be developed based on typical clinical 
constraints used for designing treatment plans for brain cancer targets at the 
Proton Therapy Center – Houston (PTC-H) and a radiation oncologist will review 
and approve the final plans.  
3. Radiochromic film and TLD capsules will be placed inside the phantom’s 
cylindrical dosimetry insert and the phantom will be irradiated according to the 
treatment plan. Each plan will be delivered a minimum of three separate times to 
assess reproducibility of the phantom audit system. 
4. The 2D dose distributions and absolute point doses determined from the film and 
TLD will be compared with the calculated values of point doses, dose profiles and 
planar dose distributions from the treatment planning system to determine the 
agreement and reproducibility. 
1.4 Limitations 
There are two primary challenges in the development of a head phantom that can be 
used to audit proton therapy for targets in the head. The first challenge is the creation of a 
phantom that can be imaged appropriately. The latest Radiation Therapy Oncology Group 
(RTOG) protocol, RTOG 0539, on the treatment of Meningioma requires that the head be 
imaged using MRI for the purposes of lesion delineation, and then fused with a CT image 
for dose calculation purposes (12). Anthropomorphic phantoms, however, are not usually 
imaged with MRI since the solid materials that comprise the phantoms are not well 
delineated with most MR imaging sequences. While it would be easy enough to mail out 
this phantom with instructions to take a CT image instead of MR, it is desired that the 
auditing process mirror typical treatment protocol and therefore the audit should 
encompass the imaging component of the treatment delivery process. The second 
challenge is determining what materials are to be used in the construction of the phantom 
such that they are tissue equivalent based on proton interactions. The tissue substitute 
materials used with photons do not necessarily meet the requirements to be substitute 
materials for protons. Based on these two challenges, the difficulty comes in finding 
phantom materials that are solid, tissue equivalent based on proton interactions, and show 
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up on an MRI. In addition, it is desired that the tumor be visible in the MR image, but not 
easily distinguishable on a CT image.  
The RTOG 0539 protocol also recommends head immobilization tactics such as 
cast immobilization, modified stereotactic frame, or a camera-based localization setup 
(12). These requirements are hard to meet due to the structure and solid nature of the 
phantom, so special considerations have to be made for phantom immobilization. The 
protocol also requires that weekly portal imaging be used for the initial treatment setup, 
as well as periodically throughout the course of treatment (film or EPID). While the 
periodic imaging cannot be integrated into phantom irradiations, the initial treatment 
setup will utilize on-board imaging. 
1.5 Literature Review 
1.5.1 Proton Background 
Proton therapy has long been of interest in the medical community due to the 
behavior of protons in a medium. The existence of protons was suggested by Rutherford 
in 1919 and the first particle accelerator was developed in 1930; 16 years later, it was 
suggested that protons could be used for treatment of cancer (13, 14). What is exciting 
about proton therapy is that protons, basic subatomic charged particles, follow the theory 
of the continuous slowing down approximation, and the rate of energy loss of a proton 
particle is found to be inversely proportional to the square of its velocity (15). As a 
proton collides with other particles in a medium and experiences a decrease in velocity, 
the energy loss is greatly increased causing a characteristic energy deposition known as 
the Bragg peak. When beams of different energies are superimposed to create a spread 
out  Bragg peak (SOBP) in depth, the area of high energy deposition can be used to treat 
a tumor of finite thickness as seen in Figure 1.1. In addition to the high dose region of an 
SOBP, protons exhibit relatively low energy deposition on the proximal side of the peak, 
and extremely low amounts of energy deposited on the distal side of the peak (13). This 
is an advantage (in theory) of protons over more conventional therapeutic modalities such 
as electrons, which have a higher relative entrance dose for both skin and proximal target 
tissues, and photons, which exhibit a greater distal dose, as shown in Figure 1.1.  
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Figure 1.1 Relative Depth-Dose curves of 6 MV photons, 20 MeV electrons, pristine 
200 MeV protons, and a spread-out 200 MeV proton beam 
The steep energy drop-off on the distal side of the proton SOBP means that the 
dose prescribed to the lesion can deliver a highly conformal dose while sparing the 
healthy tissue, or perhaps an organ at risk, especially that is located distal to the range of 
the proton beam, indicating a possible advantage over photon therapy.  
When a proton interacts with matter, it loses small portions of its energy due to 
electromagnetic interactions with atomic electrons (15). The quantification of a proton’s 
energy loss over a finite thickness of absorbing material is defined by the term mass 
stopping power. The mass stopping power can be expressed as below (16): 
    

   
	
²²²
²     Equation 1.1 
 	
²²²²    Equation 1.1 takes into 
account the radius of the electron orbit (r), the rest energy of an electron (mc2), the atomic 
number of the stopping material (Z), the charge of the proton (z), the ratio of the proton’s 
velocity to the speed of light (β²), the atomic mass unit (u), the atomic mass of the 
stopping material (A), and the stopping number (L(β)). The mass stopping power value 
takes into account the mean excitation energy of atoms in the stopping material, the effect 
of atomic shells, and the density-effect, or the effective reduction of stopping power due 
to the proton’s projectile polarization (16). 
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1.5.2  Biological Impact of Protons 
In addition to the advantages that protons present due to their characteristic range, 
protons are thought to have a greater biological impact than other therapeutic particles, 
which can be more effective in causing damage in cancer cells. This higher biological 
impact is caused by an increase in ionization along the path of the particle. Relative 
biological effectiveness (RBE) is expressed as:  
           
     Equation 1.2  
In  
     Equation 1.2, Dose and Doseref are the doses 
required to cause the same biological effect. The reference dose, Doseref, is based upon 
either 60Co or 250 kVp photons (17). When using such a reference dose, an RBE of 1.1 is 
generally accepted and used for protons (11, 18, 19). This means that protons themselves 
have a higher RBE than conventional treatment with photons and electrons. In addition, 
nuclear reactions with protons cause secondary particles (such as neutrons) that have 
greater RBE, and can be more effective in killing the cells that make up cancerous lesions 
(15). 
When speaking of dose delivered by protons, the RBE is usually taken into 
account and the dose is expressed in terms of Cobalt Gray Equivalent (CGE). The 
equation for CGE for protons is listed in        .    
!"                
Equation 1.3 (20, 21): 
                                         .    
!"                Equation 1.3 
The above equation gives a value for dose, expressed in units of Gray (Gy), that is 
comparable to photon or electron dose that have an RBE equal to 1.0. For uniformity and 
clarity purposes, the NCI requires that radiation therapy groups participating in clinical 
trials use CGE for dose information and prescription (11). It should be noted, however, 
that many proton clinics are using the unit of GyRBE in reference to RBE dose.  
1.5.3 Proton Therapy Beam Development 
Protons used for therapy purposes are generally 
The two most basic categories of proton 
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1.5.3.1 Passive Scattering  
When the accelerated protons reach the gantry, 
The SOBP is created by beam range 
 
 
Figure 1.2. Range Modulation Wheel (5) 
12 
 
 
Figure 1.3. 160 (ID84) and 140 (ID85) MeV RMWs used at the PTC-H 
The range of the protons can also be varied by inserting additional absorbers in the beam 
path, as well as by changing the energy of the beam (18). At the PTC-H, range shifters 
are introduced after the scatterers and RMW to shift the beam range in increments of 1 
mm. 
The passive scatter beam is also shaped by apertures and compensators (see Section 
2.3.2.1 for images). The apertures are thick sheets of brass that are shaped according to 
the outline of the target and placed on the outer edge of the treatment snout. These block 
the protons outer transverse region of the lateral spread. Often two or three apertures are 
used in treatment, depending on the energy of the beam used (higher energy beams 
require a greater thickness of attenuator to block the field). The compensator is placed 
immediately after the apertures. This allows proton beams to be molded to three-
dimensional objects, such as tumors. The compensator is usually made of acrylic and 
shaped to the distal edge of the field using a computer-controlled raster drilling pattern.  
1.5.3.2 Spot Scanning 
For scanning proton beams, a pencil beam is 
 For the PTC-H’s spot scanning system, the 
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1.5.4 Dose Uncertainties 
The range can be a source of uncertainty with proton beams. If the energy modulation is 
not accurately implemented or achieved, the SOBP may deviate from what is expected.  
This can result in underdosing the target or overdosing normal tissue.  
There is also uncertainty introduced by the heterogeneity of the absorbing materials. The 
manner in which the proton beam range is varied mirrors the way in which the range can 
be changed in other absorbing materials, such as the human body. A section of high or 
low density tissue can cause a shift in the range of protons if not properly accounted for 
in treatment planning models. If the treatment planning system does not accurately model 
the heterogeneities of the absorbing tissues, the dose delivered could be different from 
what is predicted. This demonstrates the need for stringent quality assurance and 
attention to detail on the part of the radiation therapy team. 
1.5.5 Beam Monitoring 
As the beam modulators cause variability in 
1.5.6 Dose Distribution Measurements 
In addition to monitoring the beam output, it is important to characterize the dose 
distribution of the proton therapy systems to have an illustration of the behavior of the 
beam for treatment planning and delivery purposes. As mentioned in the previous section, 
ion chambers can be used to monitor the beam output at the treatment head as well as 
depth dose profiles. 2D dose distributions can be captured using either radiochromic film 
or 2D ion chamber arrays (24, 26). The measurements of 2D dose distribution are useful 
in patient specific QA at proton therapy facilities.  
1.5.7 Proton Therapy in Treatment of Brain Tumors 
When developing the phantom, some thought 
Meningiomas arise from the meninges, or 
Proton therapy in particular is a good treatment 
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2 Methodology 
2.1 Phantom Design 
2.1.1 Previous Phantom Designs 
As part of the RPC’s role in remote monitoring of institutions that participate in clinical 
trials, the center has created a number of mail-able dosimeter systems and phantoms. The 
phantom program at the RPC has utilized a variety of creative scientific minds to create 
heterogeneous phantoms for different regions of the body. There is an obvious advantage 
to heterogeneous over homogeneous phantoms, as the body itself has a diverse 
composition. More specifically, the RPC strives to create anthropomorphic 
heterogeneous phantoms, which are not only varied in their composition, but mimic 
anatomical composition. Some anthropomorphic phantoms, such as the one developed at 
the RPC for the evaluation of Intensity-Modulated Radiation Therapy (IMRT), are 
constructed with a tissue-equivalent surface and filled with water, while materials are 
placed inside with tissue-equivalence to tumors and/or critical structures (31, 32). Water 
is a good option for tissue-equivalent material, but it can be problematic. Air bubbles in 
the water in the phantom can cause discrepancies in imaging, treatment simulation, and 
dosimetry. In addition, water residue can cause mold to form in crevices of the phantom 
material if not properly cleaned. This is particularly the case in a phantom that includes 
real bones, such as a human skull. 
The Alderson Average-Man phantom was created with a human skeleton cast in a 
synthetic isocyanate rubber (33). The material of the phantom is tissue-equivalent and 
durable, and can be cast around human bone as well as carved to represent anatomical 
airways, making it a good option for a phantom to be sent to a customer or external 
institution. 
Phantoms designed by the RPC use various 
2.1.2  The Anthropomorphic Head Phantom 
Because there is still some uncertainty as to the 
The phantom for this project was created with 
Once the materials were measured and deemed 
Axial CT images of the phantom were obtained 
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Figure 2.1. Head phantom 
A hole of 7 cm in diameter was drilled 
 
Figure 2.2. Insert hole in phantom 
The imaging insert was developed for the 
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 a.         b.  
Figure 2.3.  MRI insert sketch (a.) and physical insert (b.), made of hollow acrylic 
with nylon ball suspended from the superior surface 
The CT/irradiation insert is designed as a high 
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Figure 2.4. Dosimetry insert schematic of 
This insert does not have a tumor embedded, 
 
Left 
Post. 
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Figure 2.5. Solid polyethylene dosimetry insert, with irradiated film and right TLD 
capsule shown 
Once the phantom is created, the next step is to 
2.1.3 Determining Tissue Substitutes for Proton Therapy 
To design the heterogeneous phantom, it was 
The relative stopping powers of potential phantom materials were determined with the 
passive scattering proton beams at the UT MD Anderson Proton Therapy Center of 
Houston (PTC-H). The materials studied consisted of two different types of epolene, Mix 
D plastic, a solid wax, and the solid material that makes up Alderson Rando phantom 
material, all of which are supposedly water-equivalent materials (with respect to photon 
therapy).  
The PTC-H’s 3D PTW MP3 scanning water 
At each measurement position, a four second 
In order to determine the relative stopping 
Once the data were recorded for both the water 
To calculate the relative stopping power of each material, the depths of the distal 
80% points were calculated using a linear slope formula between the two data points 
straddling the distal 80% for both the water only and water plus slab depth dose curves. It 
19 
 
is the preference of some to use the distal 90% points instead (35). However, it was 
recommended that for the purposes of this experiment the distal 80% be used (36). As 
long as the same two percent depth dose points are being compared, the relative stopping 
power relationship will hold because only the shift in depth between the two depth dose 
curves is being observed, and all points along the curve should shift by the same amount. 
A linear regression was performed on the distal 80% points. Then, the relative stopping 
# $%!&!
%&' !$%("+                    Equation 2.1 (37). 
                                     #  * # $%!&!
%&' !$%("+ +                     Equation 2.1 
A relative stopping power close to unity was desirable (meaning the material had 
a stopping power close to that of water).  
The phantom materials of interest were scanned with the Proton Center’s CT 
machine, a GE LightSpeed RT16 (GE Healthcare, Waukesha, WI) to measure their 
Hounsfield units. The materials were taped to the CT machine table which was aligned 
with the lasers. An imaging technique of 120 kV and 300 mAs was used for the CT scans 
of epolene and Mix D, while 120 kV and 350 mAs were used for “wax” and Alderson 
material. The difference in technique was due to different technologists operating the 
machines, but the small variation in mAs should not affect the CT number of the 
materials, so the discrepancy was not a concern for the measurements. For both imaging 
techniques, the scans were done in the fast helical setting with a pitch close to 1 and using 
the head Scan Field of View. The CT numbers were obtained using the Eclipse treatment 
planning system (Varian Medical Systems, Palo Alto, CA), taking the average of 10 
measurements made across a central image of the material.    
Once the RTOG 0539 protocol was reviewed, it was determined that to stay true 
to common meningioma treatment procedures, the phantom needed to be imaged with 
MRI for treatment planning. It was unclear initially whether or not the phantom material 
would show up on an MR image due to its solid state. To determine whether or not this 
was the case, an old anthropomorphic phantom from the RPC was imaged to see if any 
parts were visible or distinguishable. A GE Signa HDxt 1.5 Tesla research scanner (GE 
Healthcare, Waukesha, WI) at MD Anderson Cancer Center was used. The phantom was 
placed in the supine position in an 8 channel array head coil. An initial localizer scout 
was performed to see if any signal was detected. A fast spin echo was used due to the 
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short time of T2* of solid materials. When a signal was detected, a second image was 
obtained for an axial cross section of the mid-skull area. Surprisingly, a fairly detailed 
image was obtained from this scan in which the outer shape of the phantom as well as 
bony anatomy and air pockets inside were easily visible. An image with a greater scan 
extent was then obtained using a more pertinent scan setting with a steady state free 
precession acquisition, which for the GE machine was 3D Fiesta C. The contours of 
bone, phantom material, and air were all still visible. 
For MR images for treatment planning, RTOG 0359 recommends obtaining T1, T2, 
FLAIR, and postcontrast multiplanar T1 images (12). The protocol says Gadolinium 
contrast agent should be administered per institutional policy. Both of these 
recommendations should be kept in mind for patient imaging, but were impractical for 
phantom imaging, and as will be discussed further in Section 2.3.1.1, only one MR 
sequence image set was used for the phantom simulation and treatment planning. 
2.2 Developing the Phantom Components for Precise Setup 
Patient setup was an important part of developing the phantom. For reproducibility 
purposes, it was desired that the phantom have some kind of apparatus that would allow 
for the precise setup of the phantom for imaging and treatment. Other phantoms at the 
RPC have features such as an extended base at the neck or leveling screws that support 
the head and neck phantom in a way such that it is positioned similar to a real patient’s 
head and neck during treatment.  
Per the recommendation of the PTC-H, the head & neck phantom was placed in the 
supine position. The PTC-H treatment protocol also recommends using a Head & Neck 
mask, head rest, and bite block, but it was determined that for ease of setup and 
accessibility to the dosimetry insert during re-loading, these accessories would not be 
employed. Instead, leveling screws were designed and incorporated into the base of the 
phantom in the posterior, inferior region. 
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2.3 Testing the Phantom 
2.3.1 Phantom Simulation 
2.3.1.1 MRI Simulation 
As with the phantom material scan, the MRI simulation for target delineation was 
performed on a GE Signa HDxt 1.5 Tesla scanner. The MR phantom insert, containing 
the nylon “tumor,” was carefully filled with tap water so as to minimize the number of air 
bubbles. Once the insert was placed in the phantom, the phantom was placed in an eight 
channel array head coil. The head was placed in the supine position, with the posterior 
leveling screws extended for balance. Foam blocks were placed on each side of the head 
to reduce vibration while the scan was being performed. The phantom was aligned such 
that the localizing lights were aligned to the center of the head, using the medial 
commissures of the eyes along the axial direction, and the center of the nose in the 
sagittal direction. 
A 3-plane localization was performed first to ensure proper setup. Several series 
were acquired, but the 3D SPGR, GE’s version of an RF spoiled gradient echo, was used 
for treatment planning purposes.  This series matched the volumetric CT best for fusion, 
and contained a well-delineated image of the target. An axial slice of the MR image set 
demonstrates the target delineation in Figure 2.6: 
 
 
Figure 2.6. 3D SPGR MR image at the center slice of the target 
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2.3.1.2 CT Simulation 
The CT images were acquired using the proton-dedicated GE LightSpeed RT16 
scanner at the PTC-H. The dosimetry insert was loaded with TLD and film and placed 
inside the phantom. The phantom was placed directly on the CT table in the supine 
position. The posterior leveling screws were adjusted so that the head was supported in a 
patient-like simulation fashion. Three pieces of tape were place on the head: one near 
each of the left and right temples, and one in the center of the forehead. The laser lines 
were marked on the tape, and small plastic bbs were placed at the vertex of each tape 
line. A typical proton center head protocol was used for the CT simulation. An axial slice 
of the target region of the CT images is shown in Figure 2.7, where the TLD capsules are 
delineated.  
 
 
Figure 2.7. CT image at the center slice of the target region 
The images were transferred to the PTC-H’s Eclipse treatment planning system. 
In Eclipse, the CT table was digitally replaced with the proton treatment couch. This was 
done using an in-house DICOM digital couch replacement algorithm that runs through a 
MATLAB application.  
2.3.1.3 Image Fusion 
The MR scan identifying the target and structures had to be fused with the CT 
image to identify the target within the CT images to complete the treatment planning and 
dose calculation process. For the image fusion, the Eclipse mutually shared algorithm 
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was used. The region of interest was limited to the head. The algorithm’s registration uses 
“manual tools” to translate the images for a generic match, then pixel registration for a 
more detailed fusion guided by bony anatomy alignment. The “blend with” view can be 
used to slide over the MR and CT images to see how closely the algorithm matched the 
images.  
2.3.2 Treatment Planning 
Once an acceptable fusion was achieved, the target volume was contoured. The 2 
cm diameter ball was designated as the GTV, and the PTV was created with a 0.5 cm 
expansion in all directions, per RTOG 0539 specifications. Both passive scattering and 
spot scanning proton beam plans were created. The dose prescription was 54 CGE, but 
for the purposes of the project, the plans were created to deliver 5.4 CGE to the target 
volume one time. This is a dose one-tenth the size of the prescribed dose was given to the 
phantom target, per typical RPC protocol for head & neck phantoms (31). This lower 
dose was chosen to accommodate the dose range of the Gafchromic film used in the 
dosimetry insert. Per the RTOG 0539 specifications, all dose constraints were scaled to 
10 percent of their original values. This meant that the 5.4 CGE must cover ≥ 95% of the 
PTV, that the minimum dose to the PTV be at least 5.1 CGE, and that the maximum dose 
to any point (≥ 0.03 cc) not exceed 6.2 CGE (12). Treatment plans were created using 
both the passive scattering and spot scanning proton beams at the PTC-H. Digitally 
Reconstructed Radiograph (DRR) images were also created in the treatment plans for 
comparison with radiographs that were to be acquired before each treatment for 
localization purposes. 
2.3.2.1 Passive Scattering Plan 
The passive scattering plan was designed using three beams: a posterior-anterior, 
left vertex, and right vertex beam. The beams were equally weighted to deliver 5.4 Gy 
(5.94 CGE) and combined to form a rough-edged uniform-dose sphere surrounding the 
target volume. It is important to note that the passive scattering treatment plan was 
initially designed with the intention of delivering 5.4 CGE to the target. However, when 
the MU calculations were performed, the RBE was not accounted for and the dose 
delivered to the phantom target was actually a physical 5.4 Gy.  
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The isodose distributions are shown in Figure 2.8, and the beam parameters are 
listed below in Table 2.1. 
 
         a.             b.  
Figure 2.8. Passive Scattering treatment plan shown in the coronal (a) and sagittal 
(b) planes 
 
Passive Scattering Treatment Plan 
Prescribed Dose: 540 cGy 
Beam A B C 
Beam Name 
 Posterior-
Anterior 
Left 
Vertex 
Right 
Vertex 
Beam Energy [MeV] 160 140 140 
Gantry Angle 180º 75º 285º 
Couch Angle 0º 320º 40º 
Snout Position [cm] 30 25 25 
Dose to isocenter [cGy] 181.9 181.3 182.2 
Table 2.1. Passive Scattering treatment plan parameters 
For each field, two brass apertures (Figure 2.9) and one compensator (Figure 
2.10) were created at the in-house PTC-H machine shop and checked against the 
treatment plan specifications. 
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Figure 2.9. Passive Scattering beam aperture 
 
Figure 2.10. Passive Scattering beam compensators for (from left to right) beams A, 
C, and B 
The phantom was irradiated on the G1 passive scatter gantry at the PTC-H. The 
treatment plan for the phantom had been created for the G2 gantry, so despite the beams 
being matched (within one percent), the Digital Imaging and Communications in 
Medicine (DICOM) commands had to be converted to the right syntax for the G1 gantry. 
This was accomplished by using a DICOM editor and changing the beam modulation ID 
from 84 to 20 for the 160 MeV beam, and from 85 to 21 for the 140 MeV beam, as well 
as a few other beam identifiers.  
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The monitor units (MU) were calculated for each field based on                     
,-  "
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0# 01   Equation 2.2:  
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  The relative output factor, range 
Passive Scatter Treatment Plan 
Prescribed Dose: 540 cGy 
Beam A B C 
Dose to isocenter [cGy] 181.9 181.3 182.2 
Relative Output Factor 0.865 0.927 0.927 
Range Shifter Factor 0.967 0.981 0.996 
SOBP Factor 1.295 1.073 1.073 
MU Delivered 167.4 185.3 182.0 
Table 2.2. Monitor Unit (MU) parameters for the passive scattering treatment fields 
2.3.2.2 Spot Scanning Plan 
The spot scanning plan was designed using the 
          a.       b.  
Figure 2.11. Spot scanning treatment plan shown in the coronal (a) and sagittal (b) 
planes 
The beam parameters are listed below in  
Spot Scanning Treatment Plan 
Prescribed Dose: 540 CcGyE 
Beam A B 
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Beam Name Left Right 
Nominal Beam 108 113.4 
Nominal SOBP 3.2 3.37 
Gantry Angle 90º 270º 
Couch Angle 315º 45º 
Snout Position 38 38 
Dose [CcGyE] 270 270 
MU 63.6 62.5 
Table 2.3: 
Spot Scanning Treatment Plan 
Prescribed Dose: 540 CcGyE 
Beam A B 
Beam Name Left Vertex Right Vertex 
Nominal Beam Energy [MeV] 108 113.4 
Nominal SOBP Width [cm] 3.2 3.37 
Gantry Angle 90º 270º 
Couch Angle 315º 45º 
Snout Position [cm] 38 38 
Dose [CcGyE] 270 270 
MU 63.6 62.5 
Table 2.3. Spot scanning treatment plan parameters 
The phantom was irradiated on the G3 spot scanning beam at the PTC-H on. The monitor 
units for this plan are calculated by the Eclipse treatment planning system, so a manual 
MU calculation was not required for this plan, as was the case for the passive scattering 
plan. 
2.3.3 Treatment Delivery 
2.3.3.1 Passive Scattering Irradiations 
The phantom was set up in the supine 
Orientation Nozzle Cage 
kVp 65 65 
mA 630 500 
ms 80 60 
Table 2.4.  kV imaging parameters for PTC-H proton treatment setup 
The x-ray images were compared to DRRs 
The first passive scattering irradiation trial 
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Once the first trial irradiation was delivered, 
Once the phantom was reloaded with unirradiated dosimeters, it was repositioned on the 
treatment couch using the lasers to align with the new tape markings. For the second 
irradiation trial, the leveling screws at the base of the phantom were adjusted so the tape 
markings aligned with the lasers, as it was determined that the screws had been bumped 
during reloading. Another set of x-rays was acquired to verify the positioning of the 
phantom. No adjustments were made to the phantom or the couch. The film and TLD 
were reloaded again for the third trial irradiation, and the fields were verified with x-ray 
images.  
2.3.3.2 Spot Scanning Irradiations 
For irradiation, the dosimetry insert was 
The treatment plan had been designed to deliver 54 CGE over the course of 10 fractions, 
so only the first fraction was delivered for each trial, for a dose of 5.4 CGE. The first spot 
scanning irradiation trial was irradiated according to the treatment plan, with the left 
vertex beam, beam A, delivered first. Beam A had a gantry angle of 90º, a couch angle of 
315º and a nominal beam energy of 108 MeV. Beam B, the right vertex, was delivered 
next, with a gantry angle of 270º, a couch angle of 45º, and nominal beam energy of 
113.4 MeV, which is the energy of the proton spots with the distal 90% range at the 
deepest layer. 
Once Trial 1 irradiation was delivered, the phantom was removed from the couch and 
reloaded with TLD and film. Again, x-ray imaging was used to assess phantom alignment 
before the doses were delivered and calculate necessary couch shifts. The same procedure 
was followed for the third trial as well.  
2.3.4 TLD 
2.3.4.1 Absolute Dose Determination 
The RPC has developed a mailable TLD 
Thermoluminescent dosimeters were used to measure 
2 × × × ×1  Equation 2.3 will be used: 
      2  ×  ×  ×  × 1  Equation 2.3 
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 The dose measured from TLD is calculated 
The sensitivity correction factor is perhaps the most important as it can vary 
between individual readout sessions due to factors such as system electronics and the 
reader planchette (41). The correction factor looks at the system sensitivity (dose per 
reading) of a specific batch of TLD. S is usually calculated by irradiating TLD to a 
known dose (using an ion chamber measurement for reference) and reading out these 
TLD both before and after the TLD reading session. This factor can be measured by 
dividing the known dose by the TLD response for those measurements (T’) and 
("4"2′ ×′×1′    Equation 2.4: 
       ("4"26 ×6×16     Equation 2.4 
where L’ and T’ are the relative linearity and fading factors of the TLD powder batch.  
The energy correction factor takes into account that TLD crystals have a small 
energy dependence. The factor is found by comparing the output per dose of a TLD at a 
60Co energy (reference energy) to the energy of a proton beam. This TLD proton energy 
correction factor was determined to be the same for all proton energies tested by the RPC 
and is unity.  
The linearity correction factor accounts for the slight non-linearity of TLD 
response over a wide range of doses. To find this correction factor, several TLD were 
irradiated over a range of doses. For low doses, there is a linear adjustment that needs to 
be made, but at higher doses, the relationship becomes logarithmic. In the dose range we 
used, the linearity correction factor is found with inverse of response of the TLD 
response v. dose curve, as described in the following =&  + 7  
 Equation 2.5: 
  &   + 7   Equation 2.5 
 
where a and b are coefficients specific to each batch of TLD.  
The fading correction factor takes into account the recombination of some 
electron-hole pairs before the TLD dosimeter is read out. The RPC uses a double 
exponential fading correction factor based on a plot of time v. percent of signal obtained 
in readout: 
1   .889:!; 9.!   Equation 2.6 
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The change in the fading correction is minimized by waiting a minimum of 14 
days after irradiation to read out the dosimeters. The RPC uses the same fading curve for 
all batches of TLD as there is little variation in this correction factor when the minimum 
readout time is standardized. 
The TLD in the phantom for each irradiation consisted of two double-loaded LiF 
TLD-100 dosimeters (Quantaflux, LLC, Dayton, OH). Each capsule was placed 3 mm off 
axis, one above and one below the center line.  
2.3.4.2 TLD Characterization 
The TLD batch used for the project was named batch B07 and had been 
characterized by the RPC prior to irradiation. As discussed in the previous section, 
correction factors are needed for calculation of TLD dose. For the linearity correction 
factor for the batch of TLD used the slope (m) and y-intercept (b) found in =&  +
7   Equation 2.5 are -0.00027842 and 1.08353, respectively. For the 
fading correction factor, the 1   .889:!; 9.!  Equation 2.6 parameters are 
listed in Table 2.5. 
N 1.3493 
a 1.2815 
b 0.00010885 
c 0.06781 
d 0.071908 
x Days between irradiation and reading 
Table 2.5. TLD fading correction factor constants 
 
2.3.4.3 TLD Evaluation 
The TLDs were read out after 21-23 days, so as to minimize the effects of fading. 
The TLD was read in between a series of standard and control TLD which had been 
irradiated using the ADCL’s 60Co machine. An unexposed TLD-100 pack was used as the 
background, and its reading was subtracted out from the readings of the exposed TLD. 
  2  ×  ×  ×  × 1  Equation 2.3 was then used to calculate the 
dose delivered to each TLD. TLD have been found in some cases to underestimate proton 
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dose by about 7%, but this is mostly due to positioning errors (38). In a previous study 
done by the RPC for the development of a head & neck phantom, TLD dosimeters were 
found to have an accuracy of ± 4% and precision of ± 3%  at a 90 % confidence interval 
(31). 
For this experiment, a ratio between calculated TLD dose (based on the treatment 
planning model) and measured TLD dose would be deemed acceptable within the range 
of 0.95-1.05 in order to meet the 5% point dose agreement criterion. The coefficient of 
variation was used to calculate reproducibility, and COV values of less than 3% were 
considered passable. 
In order to test statistical significance of the TLD results, a one-sample t-test was 
performed with a significance level of 0.05. The t-test values was computed using the 
equation below (42): 
     !   <̄> ?
√"A
    Equation 2.7 
where x̄  is the mean ratio of calculated v. measured TLD dose, CDis the null hypothesis, 
which we define to be 0.949 (outside of the 5% limit, where s is the standard deviation 
and n is the sample size, three trials. The critical value was found using the TDIST 
function, which yields the probability for a t-test distribution. The statistical significance 
was found by finding the p-value, which if less than 0.05 was said to be statistically 
significant. If the p-value was greater than 0.05, the data would be considered not 
statistically significant, and the hypothesis would be rejected. 
2.3.5 Film 
Another passive dosimeter that can be used effectively in a mailable monitoring program 
is radiochromic film. The RPC already uses this film as part of its mailable dosimetry 
program. Radiochromic film is a good option for finding the dose distribution of a 
radiation beam, as it exhibits no angular dependence, a high spatial resolution, and a low 
spectral sensitivity (31). Another advantage of radiochromic film is that it is tissue-
equivalent, so as a beam passes through it, the behavior of the particles shouldn’t be 
disrupted (43).  
Gafchromic® EBT2 is yellow in color and uses a 
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Polyester Overlaminate (50 µm) 
Adhesive (25 µm) 
Topcoat (5 µm) 
Active Layer (20 µm) 
Polyester Substrate (175 µm) 
Figure 2.12 Design of Gafchromic® EBT2 film showing the various layers of the 
film 
One advantage of EBT2 film over 
In order to assure accuracy of the film measurements, the film was calibrated with 
a passive scatter beam at the PTC-H. Six doses were chosen for irradiation: 50, 150, 250, 
350, 550, and 750 CcGE. These doses were chosen because they are the standard doses 
delivered for photon beam calibrations at the RPC. The MU necessary to reach each dose 
"
./ 01&". $%!
 1&!
0# 01   Equation 2.8:  
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0# 01  Equation 2.8 
The measurements were taken in a water tank. A range shifter was not used for 
these measurements, so the range shifter factor in this case was 1. An SOBP of 5 cm was 
used, and the film was placed in the middle of the SOBP, perpendicular to the beam. An 
ion chamber was placed in the field for reference. The six dose measurements were 
collected for beam energies of both 140 MeV and 160 MeV, the energies of the passive 
scatter treatment beams.  
The films were scanned using the red light CCD Microdensitometer for 
Radiochromic Film Model CCD100 (Photoelectron Corporation, Lexington, MA) at the 
RPC. A flat field adjustment was made using a blank piece of film from the same batch. 
The average optical densities were obtained for each dose using ImageJ software 
(Rasband 1997-2011), and a calibration curve was created with a third degree polynomial 
fit.  
It was determined that creating a proper dose response curve for the spot scanning 
system was beyond the scope of this project. Other studies, such as one performed by 
Zhao et al., have found the OD-dose calibration curve of spot scanning systems similar to 
that of scattered beams (46). As such, it was decided that a measurement of a uniform 
field of a known dose with the spot scanning system could be compared to the passive 
scattering dose response curves, and if that dose was within 5% of what was predicted by 
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the polynomial fit, the passive scattering dose response curve would be used. A uniform 
10x10 cm2 spot scanning beam with an SOBP of 10 cm was delivered to a piece of film 
from the same batch. The OD-dependent dose measured was compared to the dose 
delivered. 
Film was placed in the coronal and sagittal planes of the dosimetry insert in order 
to observe the dose distribution of the proton treatment. The film was all cut using the 
same template, and each coronal piece was cut in half to allow the sagittal piece to 
intersect it in the middle of the target location.  
EBT2 film should always be scanned in the same direction and with the same 
orientation. To ensure this process, the pieces of film were marked with permanent 
marker in the outer corners, indicating orientation. It was recommended by International 
Specialty Products, the manufacturer of this film, that the film rest for at least 24 hours 
before being read out to ensure dose accuracy (44). The films used in the phantom 
irradiations were read out after two days. 
2.3.6 Film, TLD, & CT Registration 
The film and TLD needed to be registered with the CT images for analysis 
between the treatment plan dose clouds and dose delivered. The RPC uses in-house 
developed software called rpcfilm that registers CT images and the dose distribution with 
TLD and film locations and the corresponding measured dose distributions.  
Pin pricks on the film provide spatial orientation and convenient registration 
points for the program. It is necessary to set a central axis and measure the distance 
between the pin pricks and that origin. This was done using the isocenter of the target as 
the origin. Pricked pieces of film were placed on grid paper for alignment and the 
coordinates of the pin pricks were measured using calipers. These coordinates were 
entered into the excel file under the corresponding “sagittal” and “coronal” labels. The 
CT images were registered to the system by setting the center of the target as isocenter 
and measuring the distance to four pins in the dosimetry insert.  
Once the irradiated film has been scanned into the system and is pulled up in 
rpcfilm program, the pin-pricks can be identified and the spatial orientation of the film is 
registered on one coordinate system, as delineated in Figure 2.13. The CT image set is 
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opened with Computational Environment for Radiotherapy Research (CERR) software 
and pins are used to mark the spatial coordinates and register the images to a second 
coordinate system. The program then uses the program CERR to register both the film 
and the CT image set to a third set of coordinates so that the two can be compared.  
 
 
Figure 2.13. Pin pricks from coronal film picked for registration with pre-measured 
points 
When the registration occurs for both the film and the treatment plan image 
coordinate systems, error in the form of root mean square (RMS) is calculated by the 
rpcfilm program to assess the goodness of fit. The upper limit on the RMS for our point 
registration was set at 1mm so as to minimize propagation of error. These errors are 
recorded as “RMS Error” for film registration and “RMS 3D” for CT image registration, 
as shown in Figure 2.14. 
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Figure 2.14. The RMS errors for film and CT registration, as displayed in 
MATLAB 
When the film is properly registered, a dose response calibration curve is applied 
to convert the optical density of the film to dose. The TLD positions are also recorded 
based on the center of the active portion of the capsules in relation to the film coordinate 
system. The dose grid of the film is scaled using the TLD dose, which is applied to the 
points on the film where the TLD capsules have been assigned. The doses for the rest of 
the film profile adjust accordingly. 
2.3.7 2D Gamma Analysis 
The agreement between 2D dose distributions was evaluated using a gamma 
analysis procedure, with dose or distance agreement criteria of both ±5%/3mm and 
±5%/5mm. The comparison analysis can be performed once the CT data and film had 
been registered. A data omission mask was applied to regions of the film that we did not 
want included, such as the pin pricks, pen marks, and the strip between the two pieces of 
coronal film, as seen below in Figure 2.15. The RPC uses a pixel pass rate of 85% for 
gamma analysis, so the same criterion was used for this project. 
 
Figure 2.15. Masks applied to the coronal film to avoid comparison between 
compromised areas 
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2.3.8 Distance to Agreement Measurements 
With the dose profiles created by the gamma analysis in the rpcfilm program, 
distance to agreement (DTA) measurements could be calculated between the treatment 
planning system and the delivered dose profiles. These measurements were calculated in 
the regions of steep dose fall-off beyond the target. This is done by fitting a regression 
line to the dose fall-off regions, starting at the 80% dose point and extending to down as 
far as the 30% dose point. The distance in millimeters is then measured between where 
these dose points fall in the planned dose distribution and on the film. An average 
displacement for each side of the target is then calculated (i.e. +/- mm shift left/right, 
superior/inferior, anterior/posterior). With our gamma analysis acceptance criteria of 
±5%/3mm, it is desired that the DTA measurements are less than 3 mm, and less than 5 
mm for the loser ±5%/5mm criteria. While the gamma analysis tells us the percentage of 
pixels that pass the criteria, the DTA measurement quantifies the average shift between 
treatment planning dose and delivered dose. 
 
  
37 
 
3 Results 
3.1 Phantom Materials 
3.1.1 MR Insert Materials 
For the MR phantom insert, the relative stopping power and CT numbers were 
irrelevant to the selection of the materials, as this insert will not be irradiated with the 
proton beam, nor imaged with CT. Acrylic was chosen for the shell of the MR insert and 
the cylinder was left hollow to be filled with water. The target was made of a nylon 
sphere with a diameter of 2 cm, as discussed and shown in Section 2.1.2. 
3.1.2 Material Stopping Powers and HU 
Recalling that the purpose of the first specific aim was to find materials with 
relative stopping powers (RSP) and CT numbers close to those available in the treatment 
planning system calibration curve for tissue substitute materials, several tested materials 
will be discussed in this section. The complete results of the relative stopping power and 
HU measurements are shown below in Table 3.1. 
Materials Relative Stopping Power CT Number [HU] 
Alderson Material 1.00 16 ± 5 
Epolene 0.95 -122 ± 2 
Mix D - -11 ± 40  
Wax 1.04 7 ± 4 
Table 3.1. RSP and CT Number of materials tested for the phantom 
Epolene was found to have a promising relative stopping power as compared to 
water. However, the Hounsfield units for epolene were not close enough to water to allow 
for its use as a tissue equivalent material (-122 ± 2 HU). Another material, Mix D, had 
highly variable HU (range: -52 – 123 HU) due to the heterogeneity of the mix itself. As 
the material was not available in a more homogeneous form, it was determined ineligible 
as a tissue-equivalent material and thus not scanned with the proton beam. A waxy 
material was tested, and while its average HU was close to that of water (7 ± 4), the 
relative stopping power was not the closest to water of all the materials tested. The 
Alderson material was tested and found to have a relative stopping power and HU close 
to water, with a relative stopping power of 1.00 and a mean HU of 16 ±5. The proton 
depth dose curves measured in water with and without the Alderson material in the 
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beam’s path that were used to determine the relative stopping power of the Alderson 
material are seen in Figure 3.1: 
 
 
Figure 3.1. Depth dose curves of water and water with Alderson material present 
Due to the water-like properties of the Alderson material, it was deemed 
acceptable as a water and soft tissue substitute for the phantom. Based on stopping power 
measurements taken previously by the RPC, high density polyethylene was chosen for 
the dosimetry insert. For the purpose of comparison to the treatment planning system, the 
RSP and HU of each material is graphed along with the PTC-H Eclipse treatment 
planning system calibration curve in Figure 3.2 (5, 35). 
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Figure 3.2. HU v. RSP of materials tested compared to PTC-H Eclipse treatment 
planning system calibration curve 
The absolute error of the material thicknesses was 0.002 mm for each 
measurement, so the total error of the material thickness calculations was 0.004 mm. The 
depth dose scanning system is believed to be accurate within 0.1 mm. This gives a total 
error for the Relative Stopping Power of about 0.5%.  
3.2 Film Calibration 
The film calibration irradiations yielded dose response curves using passive 
scattering beams. The two dose response curves for 140 MeV and 160 MeV proton 
beams were compared and found to be essentially identical, as shown in Figure 3.3. 
Because of the similarity between the two curves, the 140 MeV curve fit was used for all 
data analysis. This curve was chosen because two of the three passive scattering beams 
used to irradiate the phantom were 140 MeV. The 160 MeV curve was only 1.5% 
different from the 140 MeV fit, while the “average” polynomial fit provided a 2.1% 
difference from the 140 MeV fit, so it was determined that the 140 MeV fit would be 
acceptable for all data, as it most closely represented the weighting of energies. The 
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greatest standard deviation of the optical density measurements was 0.014, and the COV 
centered around 1.0%. The equation used for film calibration in the CERR file is shown 
in Figure 3.3:  
                      LM. LM08 N  . 8O0L +  P. Q0     Equation 3.1 
 
 
Figure 3.3. Gafchromic® film proton dose response calibration curves for 140 & 160 
MeV passive scattering beams 
For assessment of the appropriateness of the passive scattering dose-response curve 
for the spot scanning system, the optical density of a uniform field of irradiated film was 
measured. The calculated dose based on the passive scattering calibration curve was 
within 5% of the measured delivered dose, which was determined to be close enough to 
allow for the use of the 140 MeV polynomial fit for the spot scanning films as well. The 
actual dose determined by the film using the calibration curve is scaled by the TLD point 
doses. Thus, as long as our calibration curve can provide a dose from film that is close to 
the expected value, the absolute dose can be determined in conjunction with the TLD 
measurements. 
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3.3 Passive Scattering Phantom Dose Measurements 
3.3.1 Absolute Dose Comparison 
The phantom doses from each passive scattering irradiation trial were measured 
with TLD and compared to the calculated doses from the Eclipse treatment planning 
system. The right anterior TLD was expected to receive a physical dose of 540 cGy and 
the left posterior TLD was expected to receive 545 cGy.  The values for the calculated 
and measured doses, as well as the ratio of the measured to calculated doses, are given in 
Table 3.2: 
 
Passive Scatter 
TLD 
Location 
Calculated Dose [cGy] 
- TPS 
Measured Dose [cGy] 
- TLD 
Meas./Calc. Dose 
 
Trial 1 
 
Right 
Anterior 540 520.9 0.965 
Left 
Posterior 545 527.8 0.968 
Trial 2 
 
Right 
Anterior 540 527.8 0.977 
Left 
Posterior 545 535.2 0.982 
Trial 3 
 
Right 
Anterior 540 528.2 0.978 
Left 
Posterior 545 534.2 0.980 
Table 3.2. Point dose comparisons between the treatment planning system and TLD 
for passive scattering 
All of the TLD measured doses were less than calculated for both positions in 
each irradiation trial, ranging from 1.8% - 3.5%. Our TLD results are found to be within 
±4% of calculated values. This is within our acceptable criteria of 5% tolerance for dose 
agreement. 
The reproducibility of the phantom measurements was computed by calculating 
the coefficient of variance (COV) between point measurements in the target. This was 
done using the average measured doses from the three trials for each TLD location and 
can be seen in Table 3.3. 
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Passive Scattering Doses 
TLD Location 
Right 
Anterior 
Left 
Posterior 
Calculated Dose [cGy] 540 545 
Measured Dose Avg. [cGy] 525.6 532.4 
COV 0.78% 0.75% 
Measured/Calculated Dose 0.973 0.977 
Table 3.3. Average of measured TLD doses from passive scattering beams for three 
trials 
The COVs for each TLD location both measure less than 0.8%, well under our 
3% reproducibility criteria. The small disparity between trial measurements show that we 
were able to set up the phantom in a reproducible fashion and that it meets the RPC 
phantom irradiation standard. These results are comparable to those mentioned in Section 
2.3.4.3, as found in the phantom study by Molineu et al., where photon phantom 
measurements were found to have 4% accuracy between various institutions. With such a 
small coefficient of variation, it may be that the lower TLD measured doses were caused 
by a systematic error due to a shift in the phantom positioning that may have been caused 
by a loose leveling screw that could have moved one or both of the TLD into a lower 
dose region. This type of small positioning error would have been hard to detect with on 
board imaging.  
3.3.2 2D Dose Distribution Analysis 
The two-dimensional dose distributions were analyzed by comparing the 
treatment planning dose clouds to the reconstructed dose profiles obtained from the 
phantom films in the coronal and sagittal planes. The film and CT registrations were 
achieved with an RMS < 1 mm for all trials, with the RMS Error ranging from 0.13-
0.8672 mm for the film, and an RMS 3D ranging from 0.75-0.9 mm for the CT images. A 
2D analysis was performed on the data, using the pass criteria of ±5%/3mm and 
±5%/5mm. The gamma analyses for passive scattering trial 1 in the sagittal plane are 
shown below in Figure 3.4. 
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a.       b. 
Figure 3.4. Passive scattering trial 1 sagittal gamma analysis (a. 5%/3mm, b. 
5%/5mm) 
The complete gamma analysis results for the passive scattering plan are listed in 
Table 3.4. 
 
Passive Scattering 
2D Gamma Percentage of Pixels Passing 
5%, 3mm 5%, 5mm 
Trial 1 
 
Coronal 91.50 98.74 
Sagittal 93.90 94.69 
Trial 2 
 
Coronal 91.28 97.63 
Sagittal 91.85 98.62 
Trial 3 
 
Coronal 88.00 96.26 
Sagittal 94.86 98.61 
Table 3.4. The gamma analysis pass rates for the passive scattering irradiations 
Using the pixel pass rate of 85% that the RPC uses, each trial passed both the 
5%/5mm and the stricter 5%/3mm gamma analyses. With the range uncertainties 
associated with proton irradiations, we expect to see some shifts in dosimetric dose 
profiles when compared with treatment planning dose clouds. As expected, the pass rates 
were greater for the 5%/5mm criteria, as it allows for a greater distance disagreement in 
pixel shifts. Overall, the sagittal films showed better pass rates than the coronal films. 
This is not too surprising, as two separate pieces of film were used in the coronal plane, 
while one solid piece was used in the sagittal plane. The left and right coronal films were 
not consistently cut from the same region of the EBT2 film, which may have caused 
some variability in dose response due to the slight variations in film composition over the 
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profile of the film. If the experiment were to be repeated, it would be done so with the 
coronal films cut from adjacent regions of the larger sheets of film. 
Despite shortcomings of the experimental design, the pass results of the gamma 
analysis are in agreement with other studies that verify dosimetry with measurements, 
such as a patient-specific QA study by Arjomandy et al. that yielded similarly high pass 
percentages (47). 
3.3.3 Distance to Agreement 
For the passive scattering trial irradiations, the distance to agreement (DTA) 
values were measured between the treatment planning system and the dose profiles 
collected from the scanned films. The average distance to agreement from the three 
irradiation trials are listed in Table 3.5. Often, DTAs are presented in overall shifts in a 
particular plane, such as 0.5 mm superior. However, as evident in Table 3.5 for the S-I 
and A-P directions, the shifts did not all occur in a unilateral direction, and the shifts in 
the L-R directions were much greater on the right side than the left. 
 
Passive Scattering 
Distance to Agreement Shifts 
Average DTA [mm] Std Deviation [mm] 
Left 0.6 0.6 
Right 3.7 0.4 
Inferior -1.1 0.6 
Superior 0.6 0.7 
Posterior -0.8 0.5 
Anterior 0.8 0.8 
Table 3.5. Distance to agreement measurements between the dose distribution from 
treatment planning system and from film measured for passive scattering proton 
beams 
For these calculations, a regression fit was calculated for the falloff regions of 
both the planning system and film profiles. Due to the relatively small size of the film 
pieces, the regression lines were calculated over varying ranges of the dose falloffs, 
always starting at the 80% dose point, but ending anywhere from the 65% dose point to 
the 30% point. The values for each profile were kept consistent for all film trials. The 
right-left profile of the coronal films is shown in Figure 3.5 with corresponding distance 
to agreement measurements. 
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Figure 3.5. Passive scattering trial 1 right-left dose profile DTAs, measured in the 
coronal plane 
As shown above in the L-R direction, there was a much greater shift observed on 
the right side of the profile than the left side. This calculation is confirmed by the gamma 
analysis in the coronal plane, where we see more pixels failing the 3mm criteria on the 
right side of the film than the 5mm criteria, as shown in Figure 3.6. 
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a.       b. 
Figure 3.6. Passive scattering trial 1 coronal gamma analysis (a. 5%/3mm, b. 
5%/5mm) with areas of greatest disagreement circled 
One set of coronal films was rescanned with adjusted alignment, but this 
realignment did not produce any improvement in the distance to agreement or pixel pass 
rates of the trial, which suggest the error in agreement originates in the actual amount of 
radiation dose delivered. However the error also could have derived from an 
inconsistency in the physical composition of the two adjacent pieces of film, or poor 
spatial registration of the film marks. 
This was not the case in the S-I shifts – as there was a relatively uniform 
contraction inward from the treatment plan dose profiles to the film, as delineated in 
Figure 3.7. The DTA measurements were taken from the 80% to 30% dose points on the 
inferior side, and the 80% to 65% dose points on the superior side. 
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Figure 3.7. Passive scattering trail 1 S-I dose profile DTAs, measured in the coronal 
plane 
As shown above, the S-I DTAs do not suggest an overall shift of the phantom, but 
rather that the dose delivered does not reach the full S-I extent that the treatment plan 
predicts. The shifts are small, however, and well within the acceptable tolerance limits of 
3mm. In Figure 3.7 it may also be the case that we observe the underresponse of film in 
the distal edges, which would agree with previous studies that show a film underresponse 
in the distal edge of the SOBP that may be attributable to an LET dependence of the film 
that results in higher recombination in the distal edge that prevents the film from 
polymerizing (43, 46, 48). 
In the A-P direction, we saw similar DTA trends as the S-I profiles. Results from 
Trial 1 are shown in Figure 3.8. The DTAs were calculated using the 80% to 65% dose 
points on the posterior side, and the 80% to 40% dose points on the anterior side. 
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Figure 3.8. Passive scattering trial 1 anterior-posterior dose profile DTAs, measured 
in the sagittal plane 
For the A-P shifts, we see minimal average DTAs that are well within the 
acceptable 3mm tolerance limits for each passive scattering trial. 
3.4 Spot Scanning Phantom Dose Measurements 
3.4.1 Absolute Dose Comparison 
For an absolute dose comparison, the TLD doses as predicted in the treatment 
planning system were compared to the measured dose from the TLD capsules in each 
trial. The ratio of measured to calculated dose is also calculated in Table 3.6. Both 
capsules were expected to receive 490 cGy. 
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Spot Scan 
TLD 
Location 
Calculated Dose [cGy] 
- TPS 
Measured Dose [cGy] 
- TLD 
Meas./Calc. Dose 
 
Trial 1 
 
Right 
Anterior 490 490.7 1.001 
Left 
Posterior 490 489.8 1.000 
Trial 2 
 
Right 
Anterior 490 489.3 0.999 
Left 
Posterior 490 490.6 1.001 
Trial 3 
 
Right 
Anterior 490 489.7 0.999 
Left 
Posterior 490 494.9 1.010 
Table 3.6. Point dose comparisons between the treatment planning system and TLD 
for spot scanning 
The data demonstrate excellent agreement between the treatment planning system 
and the TLD measurements for the spot scanning proton beam treatment plans, with a 
maximum difference of only 1%. These numbers are well within the typical uncertainty 
of TLD and within the criteria of acceptability. The agreement between measured and 
calculated values is comparable to those found by Zhu et al. when verifying patient 
specific treatment planning calculations with measured point doses (26). 
The reproducibility, as with the passive scattering plan, was calculated by 
computing the COV of the average TLD measurements for each location. The 
reproducibility is summarized in Table 3.7. 
Spot Scanning 
TLD Location 
Right 
Anterior 
Left 
Posterior 
Calculated Dose [cGy] 490 490 
Measured Dose Avg. [cGy] 489.9 491.8 
COV 0.15% 0.56% 
Measured/Calculated Dose 1.000 1.004 
Table 3.7. Average spot scanning dose over three trials 
The COV for each TLD position was less than 0.6%, which is well under the 3% 
reproducibility criterion. This indicates that the setup for the spot scanning trial 
irradiations was reproducible, and could be recreated for the purpose of future audits. 
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3.4.2 2D Dose Distribution Analysis 
As with the passive scattering treatment plan, the two-dimensional dose 
distribution was analyzed by comparing the dose clouds from the treatment planning 
system with the dose profiles from the films in the phantom. Film and CT registrations 
were all achieved with RMS < 1 mm, with the RMS Error ranging from 0.2553-0.7177 
mm for film, and a 3D RMS of 0.68 for the CT images (the CT point registration was 
used for all trials). The gamma analyses for the sagittal plane of trial 1 of the spot 
scanning plan is shown below in and the complete 2D gamma analysis results for each 
spot scanning trial are listed in Table 3.8. 
 
a.       b. 
Figure 3.9. Spot scanning trial 1 sagittal gamma analysis (a. 5%/3mm, b. 5%/5mm) 
  
Spot Scanning Doses 
2D Gamma Percentage of Pixels Passing 
5%, 3mm 5%, 5mm 
Trial 1 
 
Coronal 88.12 98.97 
Sagittal 97.32 99.91 
Trial 2 
 
Coronal 84.86 98.56 
Sagittal 98.79 99.74 
Trial 3 
 
Coronal 80.59 93.56 
Sagittal 92.89 99.74 
Table 3.8. 2D gamma analysis pass rates for the spot scanning irradiations 
The film passed well with the 5%/5mm criteria. The stricter 5%/3mm criteria 
were not met as well, with the coronal planes showing poorer pixel pass rates for every 
trial. However, the combined average pass rates for each trial all exceed the 85% pixel 
pass rate criteria set forth by the RPC, as shown in Table 3.9. 
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Spot Scanning 
2D Gamma Pass Rate – Per Trial 
5%, 3mm 5%, 5mm 
Trial 1 92.7 99.4 
Trial 2 91.8 99.2 
Trial 3 86.7 96.7 
Table 3.9. 2D gamma pass rates averaged over each trial irradiation 
When reviewing the average gamma pass rates for different planes, all show good 
agreement except the coronal plane for the 5%/3mm criteria, where the pixel pass rate 
was just under the desired 85%, as delineated in Table 3.10. However, the coronal films 
had good agreement (97%) under 5%/5mm criteria. This suggests that pixel shift is 
present between the planned dose distribution and the physical delivery in the coronal 
plane.  
 
Spot Scanning 
2D Gamma Pass Rate 
5%, 3mm 5%, 5mm 
Coronal 84.5 97.0 
Sagittal 96.3 99.8 
Sum 90.4 98.4 
Table 3.10. 2D gamma pass rates averaged by film plane 
3.4.3 Distance to Agreement 
The treatment planning dose profiles were measured against the film dose profiles 
to obtain distance to agreement values. As with the passive scattering measurements, the 
DTAs were determined in the dose falloff regions over varying ranges depending on the 
doses available on the film. These ranges were kept consistent for all trials, but varied by 
plane. The average spot scanning DTAs are shown in Table 3.11. 
Spot Scanning 
Distance to Agreement Shifts 
Average DTA [mm] Std Deviation [mm] 
Left 0.1 0.8 
Right 3.4 0.5 
Inferior -1.8 0.9 
Superior 2.2 1.7 
Posterior -1.2 0.4 
Anterior 0.0 0.5 
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Table 3.11. Distance to agreement measurements between dose distributions from 
treatment plans and from film measured for spot scanning proton beams 
As with the passive scattering irradiations, we see the greatest disagreement 
between the treatment planning system prediction and measured film dose profiles in the 
coronal plane in the L-R direction. The distance to agreement measurements were 
calculated between the 80% and 50% dose points for both the left and right sides for all 
trials. This dose profile is shown in Figure 3.10.   
 
 
Figure 3.10. Spot scanning trial 1 right-left dose profile DTAs, measured in the 
coronal plane 
The left side of the dose profile shows good agreement between the TPS and film, 
but the right side has much greater average displacement, with film doses not reaching as 
far as the treatment planning system predicts. This right side displacement is greater than 
the 3mm we desire for the stricter criteria, as highlighted in the circled areas of gamma 
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analysis failure in Figure 3.11. However when we look at these same regions of interest 
within the looser 5mm standards, the gamma analysis shows better agreement.  
 
 
a.       b. 
Figure 3.11. Spot scanning trial 1 coronal gamma analysis with areas of 
disagreement highlighted (a. 5%/3mm, b. 5%/5mm) 
The disagreement highlighted in Figure 3.11is present in all of the right-left 
gamma analyses for each of the three spot scanning trials. The disagreement in the lower 
left corner of the film is most concerning, as this indicates dose to a region outside of the 
target. We suspect a small shift is responsible for this disagreement (and thus the 
disagreement is not seen on the loser 5%/5mm criteria). However the DTA calculations 
do not reflect this disagreement in the right-left profile due to the positioning of the DTA 
profile across the center of the piece of film. Taking this into account, it might be 
advantageous to run a profile and DTA measurements across a more inferior portion of 
the film plane. This would give us a more quantifiable shift calculation for the dose to the 
region of normal tissue. 
As with the passive scattering trials, the S-I DTAs suggest the film doses were 
delivered over a narrower extent than the treatment planning dose profiles, as shown 
below in Figure 3.12. The DTAs were measured from the 80% to 30% dose points on the 
inferior side, and the 80% to 50% dose points on the superior side. While the inferior 
DTA is consistently greater than the superior side, both shifts are within the 3 mm 
criteria. 
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Figure 3.12. Spot scanning trial 1 S-I dose profile DTAs, measured in the coronal 
plane 
The anterior-posterior dose profiles showed minimal shift on both the anterior and 
posterior sides. The DTAs were calculated for the dose point ranges between 80% and 
60% on the posterior side, and between 80% and 50% on the anterior side. The Trial 1 
profile comparisons are shown in Figure 3.13. The displacement on each side is less than 
1.3 mm, well within our 3 mm criteria. 
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Figure 3.13. Spot scanning trial 1 A-P dose profile DTAs, as measured in the sagittal 
plane 
3.5 Passive Scattering & Spot Scanning Results Comparison  
The passive scattering and spot scanning irradiation results are comparable under 
most criteria, but there are a few areas of distinction worth highlighting. First, though 
both systems passed the absolute point dose criteria, the passive scattering system 
showed much greater disagreement (1.8 – 3.5%) than the spot scanning system (<1%). 
However, in a previous study conducted at the PTC-H by Zullo et al., TLD-100 was 
found to predict dose within ±5% of predicted dose for passively scattered beams, which 
agrees well with our results (39). 
Another area of difference between the passive scattering and spot scanning 
systems was the gamma analysis in each film plane, as shown in Table 3.12. While the 
passive scattering system showed good agreement in the coronal plane, the spot scanning 
system showed poorer agreement in this plane. As discussed above, the lower pass rate of 
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the spot scanning system in the coronal plane was likely caused by a right-left shift of the 
phantom or dose delivery, as the spot scanning coronal gamma pass rate increases 
significantly for the 5%/5mm criteria. However there was not a larger right-left DTA 
shift observed in the spot scanning system over the passive scattering system. But as 
mentioned in Section 3.4.3, the DTA measurement is only made over a profile capturing 
a singular slice of the film plane, and as such may misrepresent the DTA over the entire 
film plane. 
2D Gamma Percentage of Pixels Passing 5%, 3mm Criteria 
Passive Scattering Spot Scanning 
Trial 1 
Coronal 91.50 88.12 
Sagittal 93.90 97.32 
Trial 2 
Coronal 91.28 84.86 
Sagittal 91.85 98.79 
Trial 3 
Coronal 88.00 80.59 
Sagittal 94.86 92.89 
Table 3.12. 2D gamma analysis pixel pass rates for 5%/3mm criteria 
Lastly, continuing the discussion of distance to agreement measurements, the 
passive scattering and spot scanning systems demonstrated comparable DTAs in every 
direction except the superior direction; the passive scattering irradiations showed a 
superior DTA of 0.6 mm, while the spot scanning irradiations had an average DTA of 2.2 
mm. These shifts are both within the limits set, but there may have been a greater error in 
positioning of the phantom during the spot scanning irradiations that contributed to a 
larger dose disagreement in the superior direction. This likely also contributed to the 
lower 2D gamma analysis pass rates of the spot scanning films in the coronal plane.  
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4 Conclusions 
4.1 Meeting Specific Aims 
This project was designed to create and test a proton therapy head phantom to be 
used for auditing proton facilities participating in clinical trials. The hypothesis was to 
see if the treatment procedure could produce measured doses that agreed with calculated 
doses within 5%/3mm with a reproducibility of 3%.  
The first specific aim, to select a head phantom design and find appropriate 
materials for the phantom construction, was achieved. The design of the phantom allows 
for easy simulation, especially with the presence of a human skull, which improves 
image-guided setup. The tissue equivalent phantom materials tested and used – the 
Alderson material, nylon, high density polyethylene, and acrylic – were all found to lie 
close to the calibration curve for stopping power and Hounsfield units used in the PTC-H 
Eclipse treatment planning system. This allowed the phantom to best simulate human 
anatomy for the target site.  
As the phantom materials were developed with the treatment process in mind, we 
were able to successfully simulate the phantom using MR and CT, with the appropriate 
phantom materials showing up well on the imaging modalities. The MR simulation was 
time consuming, which was not preferable, but the image quality was well suited for 
target delineation when the image set was fused with the CT images. Treatment plans for 
both the passive scattering and spot scanning systems were created that both met the 
modified dose constraints of the clinical trial under consideration and met the department 
standards at the PTC-H, as verified by a staff physician. The phantom was irradiated 
without problem on both the passive scattering and spot scanning proton beams at the 
PTC-H, completing the work described in specific aim two. 
Specific aim three was achieved when the point doses and dose distributions for 
each trial of each irradiation were measured by TLD and film, respectively. When 
performing the film calibration, it was discussed whether or not to include the 7.5 Gy 
data points when calculating the optical density relation. This would have made the 5.5 
Gy data point the last in the series. Since the high treatment doses expected were around 
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5.4 Gy, and some “hot” spots were anticipated, it was decided that including the 7.5 Gy 
data point was appropriate to get a better polynomial fit over the range of doses.  
Research work for specific aim four was completed by comparing the film and 
TLD results from the trial irradiations to the corresponding quantities calculated by the 
treatment planning system. The deviations and precision of the point doses and 2D dose 
calculations were measured and analyzed, and showed acceptable results according to our 
pass rate criteria set for the phantom, with an average of 91.9% of passive scattering 
pixels and 90.4% of spot scanning pixels passing 5%/3mm gamma analysis criteria, with 
a reproducibility within 0.8% for the passive scattering system and within 0.6% for the 
spot scanning system. 
There were some limitations in the accuracy of our data associated with specific 
aim four. When performing the gamma analyses for the dose distribution comparisons, 
the passive scattering analysis did not utilize the same CT registration for all trials, due to 
difficulties with the MATLAB software. This produced a range of 3D RMS errors for the 
CT registration, which may have contributed to overall uncertainty in the gamma 
analysis. If the project were to be repeated, the same CT registration would be used for all 
irradiation trials.      
The greatest area of concern with the distance to agreement shifts observed 
between film and treatment planning profiles is the large shift observed on the right side 
of the coronal films. It is unexpected that the right side shift should disagree so much 
with the left side, and for that reason it needs to be reinvestigated more carefully. One 
possible explanation of this disagreement is a rotation in the setup of the phantom head 
before irradiation. It is possible that one of the leveling screws was bumped from the 
original simulation position, which could have caused a minimal shift on one side of the 
profile and a greater disagreement on the other side. If this is the case, simply adjusting 
the resistance of the leveling screws, or creating a way of marking their level, could help 
prevent future misalignment.  
The distance to agreement measurements in the S-I and A-P directions were 
minimal and agree well with the predictions from the treatment planning system, within 
our 3 mm criterion.  
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It seems that the passive scattering plans demonstrate strong overall alignment, with the 
pixel pass rate not changing much between the 5%/3mm and 5%/5mm criteria, while the 
spot scanning treatment plans seem to show a shift disagreement, but better overall dose 
agreement between the treatment plan and dosimetric measurements. Perhaps these 
results can help the proton community better analyze the uncertainties associated with 
phantom measurements for both the passive scattering and spot scanning treatment 
delivery systems. 
The hypothesis of this project was that an anthropomorphic head phantom could be 
developed to evaluate proton therapy patient simulation, treatment planning, and 
treatment delivery to assure agreement between the measured dose and calculated dose 
within ±5%/3mm with a reproducibility of ±3%. With over 90% 5%/3mm agreement for 
both the passive scattering and spot scanning systems, and a reproducibility within 0.8% 
for both systems, the experiments support the hypothesis that a head phantom suitable for 
the evaluation of proton therapy can be created and commissioned to meet the agreement 
and reproducibility standards. 
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4.2 Clinical Significance 
As previously discussed, there is a need to verify the proton therapy treatment 
procedures for institutions participating in relevant clinical trials. With the phantom 
measurements of dose distribution showing good agreement with those from the 
treatment planning system, it can be used as a benchmark for facilities wishing to enter 
proton therapy clinical trials involving the treatment of brain tumors. The RPC would 
require that a proton therapy facility successfully complete the phantom irradiation audit 
procedure either before they treated patients on the clinical trial protocol or before a 
certain number of patients was treated. This standard of credentialing would help ensure 
that all proton therapy institutions are performing to the same high standards in order to 
ensure excellent patient care and clinically viable research trial results. This credentialing 
process not only benefits the patients participating in clinical trials, but also any patient 
that is subsequently treated on a proton therapy machine that has undergone the RPC 
phantom quality assurance process. 
4.3 Future Directions 
 
Based on the results of the study, it seems appropriate to begin use of the head 
phantom for the auditing of proton therapy treatment facilities. Initially, the phantom may 
be used on RPC site visits to participating institutions. If the phantom proves to work 
well for the site visits, the RPC should be able to incorporate it into the mailable phantom 
program. This will take some adjustment of current phantom irradiation instructions and 
procedures.  
To further improve upon the phantom design, it might be desirable to add critical 
structures to the phantom (or a new one like it) to increase the difficulty of the phantom 
irradiation, as well as collect data on the proton centers’ ability to avoid dosing such 
structures. Another future direction that was discussed throughout the course of the 
project was adapting the phantom to include a typical Head & Neck target, such as an 
oropharyngeal or nasopharyngeal tumor volume. The phantom, with its anatomical 
mimicry of nasal and oral passageways, would be well suited for a realistic experiment of 
this type. It may prove difficult to properly model human air passages, as a common 
clinical problem with treatment planning and delivery in such areas is the changing 
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volume of mucus within these cavities. This could be modeled in the phantom by 
introducing gel or a gel-filled balloon into the phantom airways, and may be a good way 
of looking at the discrepancy between the planned v. delivered doses when mucus 
volume changes. With the addition of any of these modifications, the phantom could be 
improved from its original design to adapt to the changing needs of proton therapy audits. 
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5 Appendix 
5.1 Gamma Analysis  
5.1.1 Passive Scattering Plan 
 
 
a. 5%/3mm: 91.50% pass   b. 5%/5mm: 98.74% pass 
Figure 5.1. Passive Scattering Trial 1 Coronal Gamma Analyses  
 
 
 
a. 5%/3mm: 93.90% pass   b. 5%/5mm: 94.69% pass 
Figure 5.2. Passive Scattering Trial 1 Sagittal Gamma Analyses  
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a. 5%/3mm: 91.28% pass   b. 5%/5mm: 97.63% pass 
Figure 5.3. Passive Scattering Trial 2 Coronal Gamma Analyses  
 
 
a. 5%/3mm: 91.85% pass   b. 5%/5mm: 98.62% pass 
Figure 5.4. Passive Scattering Trial 2 Sagittal Gamma Analyses  
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a. 5%/3mm: 88.0% pass   b. 5%/5mm: 96.26% pass 
Figure 5.5. Passive Scattering Trial 3 Coronal Gamma Analyses  
 
 
a. 5%/3mm: 94.86% pass   b. 5%/5mm: 98.61% pass 
Figure 5.6. Passive Scattering Trial 3 Sagittal Gamma Analyses  
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5.1.2 Spot Scanning Plan 
 
 
a. 5%/3mm: 88.12% pass   b. 5%/5mm: 98.97% pass 
Figure 5.7. Spot Scanning Trial 1 Coronal Gamma Analyses  
 
 
a. 5%/3mm: 97.32% pass   b. 5%/5mm: 99.91% pass 
Figure 5.8. Spot Scanning Trial 1 Sagittal Gamma Analyses  
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a. 5%/3mm: 84.86% pass   b. 5%/5mm: 98.56% pass 
Figure 5.9. Spot Scanning Trial 2 Coronal Gamma Analyses  
 
 
a. 5%/3mm: 98.79% pass   b. 5%/5mm: 99.74% pass 
Figure 5.10. Spot Scanning Trial 2 Sagittal Gamma Analyses 
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a. 5%/3mm: 80.59% pass   b. 5%/5mm: 93.56% pass 
Figure 5.11. Spot Scanning Trial 3 Coronal Gamma Analyses 
 
 
a. 5%/3mm: 92.89% pass   b. 5%/5mm: 99.74% pass 
Figure 5.12. Spot Scanning Trial 3 Sagittal Gamma Analyses 
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5.2 Dose Profile Comparisons 
5.2.1 Passive Scattering Plan 
5.2.1.1 Trial 1 
 
See Section 3.3.3 for trial 1 results. 
5.2.1.2 Trial 2 
 
 
Figure 5.13. Passive scattering trial 2 R-L dose profile DTAs, measured in the 
coronal plane 
0
1
2
3
4
5
6
-4 -3 -2 -1 0 1 2 3 4
D
o
se
 [
G
y
]
Lateral Position [cm]
Right-Left Profile - Coronal Plane
TPS Film Dose
Patient 
Left
Patient 
Right
-0.1 mm
0.6 mm
1.3 mm
3.6 mm
3.5 mm
3.4 mm
Average DTA:
0.6 mm
Average DTA:
3.5 mm
69 
 
 
Figure 5.14. Passive scattering trial 2 S-I dose profile DTAs, measured in the 
coronal plane 
 
Figure 5.15. Passive scattering trial 2 A-P dose profile DTAs, measured in the 
sagittal plane 
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5.2.1.3 Trial 3 
 
 
Figure 5.16. Passive scattering trial 3 L-R dose profile DTAs, measured in the 
coronal plane 
 
Figure 5.17. Passive scattering trial 3 S-I dose profile DTAs, measured in the 
coronal plane 
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Figure 5.18. Passive scattering trial 3 A-P dose profile DTAs, measured in the 
sagittal plane 
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5.2.2 Spot Scanning Plan 
5.2.2.1 Trial 1 
See Section 3.4.3 for trial 1 results. 
5.2.2.2 Trial 2 
 
 
Figure 5.19. Spot scanning trial 2 R-L dose profile DTAs, measured in the coronal 
plane 
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Figure 5.20. Spot scanning trial 2 S-I dose profile DTAs, measured in the coronal 
plane 
 
Figure 5.21. Spot scanning trial 2 A-P dose profile DTAs, measured in the sagittal 
plane 
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5.2.2.3 Trial 3 
 
 
Figure 5.22. Spot scanning trial 3 R-L dose profile DTAs, measured in the coronal 
plane 
 
Figure 5.23. Spot scanning trial 3 S-I dose profile DTAs, measured in the coronal 
plane 
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Figure 5.24. Spot scanning trial 3 A-P dose profile DTAs, measured in the sagittal 
plane 
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